NRx Pharmaceuticals, Inc.
NASDAQ:NRXPBiotechnology
+$0.06 today
- Market cap
- $124.12M
- Beta
- 2.19
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$0.76
Volume 2.09M
Average 1.27M
NRXP Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
NRx Pharmaceuticals, Inc.NASDAQ: NRXP
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$308.33M, compared with -$283.79M a year earlier.
Context
- Retained earnings amounted to 2590.3% of total assets at the end of Q1 FY2026, down 1148.6 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -8.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (306.9M) USD
- Year-over-year change
- -10.3%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (306.9M) | -10.3% |
| FY2024 | 2024-12-31 | (278.27M) | -9.9% |
| FY2023 | 2023-12-31 | (253.15M) | -13.5% |
| FY2022 | 2022-12-31 | (223M) | -21.7% |
| FY2021 | 2021-12-31 | (183.24M) | — |
Retained Earnings vs competitors
How NRXP compares with its peers on the latest reported figures
- NRXP's Mar 2026 retained earnings of -$308.33M is the 4th highest of the 9 companies compared; the peer median is -$429.46M.
- Its year-over-year change of -8.6% is the 3rd highest of 9, against a peer median of -11.3%.
- Retained earnings amounts to 2590.3% of total assets for NRXP, versus a peer median of 892.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | -$113.87M | -12.0% | — | 575.5% | |
| Mar 2026 | -$221.52M | -9.4% | — | 351.2% | |
| Mar 2026 | -$301.5M | -14.1% | — | 536.8% | |
| Mar 2026 | -$308.33M | -8.6% | — | 2590.3% | |
| Mar 2026 | -$373.64M | -5.5% | — | 1210.1% | |
| Jun 2026 | -$485.27M | -7.7% | — | 2009.0% | |
| Mar 2026 | -$633.22M | -10.7% | — | 2892.4% | |
| Mar 2026 | -$813.56M | -15.3% | — | 249.1% | |
| Mar 2026 | -$1.78B | -12.3% | — | 1355.9% | |
| Peer median (excluding NRXP) | -$429.46M | -11.3% | — | 892.8% | |
Competitors are the stored peer set for NRXP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
NRx Pharmaceuticals, Inc.
NASDAQ:NRXP
Intrinsic Alpha fair value
Locked
Current Price
$2.80
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.